Alnylam Pharmaceuticals Reports Material Agreement and Equity Sales
Ticker: ALNY · Form: 8-K · Filed: Sep 12, 2025 · CIK: 1178670
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
Related Tickers: ALNY
TL;DR
Alnylam signed a new deal, took on debt, and sold stock on Sept 12.
AI Summary
On September 12, 2025, Alnylam Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported the creation of a direct financial obligation and unregistered sales of equity securities. Specific details regarding the agreement, financial obligation, and equity sales were not provided in this filing.
Why It Matters
This filing indicates significant corporate activity, including new agreements and financial obligations, which could impact Alnylam's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing mentions material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Alnylam Pharmaceuticals, Inc. (company) — Registrant
- September 12, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Alnylam Pharmaceuticals?
The filing states that Alnylam Pharmaceuticals, Inc. entered into a material definitive agreement, but the specific details of this agreement are not disclosed in this 8-K filing.
What type of direct financial obligation was created by Alnylam Pharmaceuticals?
The filing indicates the creation of a direct financial obligation by Alnylam Pharmaceuticals, Inc., but the specific terms and amount of this obligation are not detailed in this report.
Were there any unregistered sales of equity securities by Alnylam Pharmaceuticals?
Yes, the filing reports unregistered sales of equity securities by Alnylam Pharmaceuticals, Inc., though the specifics of these sales are not provided.
What is the Commission File Number for Alnylam Pharmaceuticals, Inc.?
The Commission File Number for Alnylam Pharmaceuticals, Inc. is 001-36407.
What is the IRS Employer Identification Number for Alnylam Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Alnylam Pharmaceuticals, Inc. is 77-0602661.
Filing Stats: 1,828 words · 7 min read · ~6 pages · Grade level 10.8 · Accepted 2025-09-12 17:17:52
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share ALNY The Nasdaq
- $575.0 million — ed its previously announced offering of $575.0 million in aggregate principal amount of 0.00%
- $86.25 million — their option to purchase an additional $86.25 million in aggregate principal amount of the Co
- $661.25 million — regate principal amount of the Notes to $661.25 million. The Notes are the Company's senior uns
- $1,000 — e 1.4923 shares of the Common Stock per $1,000 principal amount of Notes, which is equ
- $670.11 — itial conversion price of approximately $670.11 per share of the Common Stock. The init
- $478.6327 — ht Time on September 9, 2025, which was $478.6327 per share. The conversion rate is subje
- $837.61 — Transactions is initially approximately $837.61 per share, which represents a premium o
- $35.3 million — actions. The Company used approximately $35.3 million of the net proceeds from the offering o
- $637.8 million — ") to repurchase for cash approximately $637.8 million aggregate principal amount of the exist
- $1,105.8 million — d and unpaid interest) of approximately $1,105.8 million. The terms of each note repurchase tran
Filing Documents
- d949176d8k.htm (8-K) — 36KB
- d949176dex41.htm (EX-4.1) — 644KB
- d949176dex101.htm (EX-10.1) — 255KB
- g949176g0912101510614.jpg (GRAPHIC) — 2KB
- g949176g0912101510755.jpg (GRAPHIC) — 2KB
- g949176g0912101510880.jpg (GRAPHIC) — 2KB
- g949176g0912101510989.jpg (GRAPHIC) — 2KB
- g949176g0912101511114.jpg (GRAPHIC) — 2KB
- g949176g0912101511224.jpg (GRAPHIC) — 3KB
- 0001193125-25-202366.txt ( ) — 1254KB
- alny-20250912.xsd (EX-101.SCH) — 3KB
- alny-20250912_lab.xml (EX-101.LAB) — 18KB
- alny-20250912_pre.xml (EX-101.PRE) — 11KB
- d949176d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 4.1* Indenture, dated as of September 12, 2025, between Alnylam Pharmaceuticals, Inc. and The Bank of New York Mellon, as trustee. 4.2* Form of 0.00% Convertible Senior Notes due 2028 (included in Exhibit 4.1). 10.1* Form of Capped Call Transaction Confirmation. 104 Cover page interactive data file (embedded within the Inline XBRL document). * Filed herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 12, 2025 ALNYLAM PHARMACEUTICALS, INC. By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief Financial Officer